Request for proposals to support independent medical education on PARP-Inhibitor combination treatments in metastatic castration-resistant prostate cancer (mCRPC), focusing on biomarker testing, safety, efficacy, and guideline-concordant care in a rapidly evolving clinical landscape.
Eligibility Criteria:
-
Applicant organizations must be based in the United States.
-
Eligible entities include medical, nursing, allied health, or pharmacy professional schools; healthcare institutions (large or small); professional societies; medical education companies; and other organizations whose mission relates to healthcare professional education or improvement.
-
Individuals or physician-owned private practices are not eligible.
-
Multi-institutional projects are permitted but all participating organizations must have a defined role, with one organization acting as prime applicant.
-
For projects offering continuing education credit, the applicant must hold U.S. accreditation.
Funding Details:
-
Individual projects may request up to $350,000 (includes direct costs plus institutional overhead, capped at 28%).
-
Total budget available under this RFP is approximately $850,000.
-
Awarded funds may cover direct educational costs, program development, and capped overhead.
-
Multi-supported (jointly funded) educational programs are encouraged.
Deadline:
Grant applications must be submitted by August 21, 2025 at 23:59 Eastern Time (GMT −5).
Where to Go for Further Information:
-
Submit via the Pfizer CyberGrants portal.
-
Select “Start A New Knowledge Gap Application,” choose “Response to a Request for Proposal (RFP),” then “2025 ONC US PARPi mCRPC IME.”
-
For questions, contact the Grant Officer, Lori Carpenter, at [email protected] (subject line: “2025 ONC US PARPi mCRPC IME”).